Compounds > prochlorperazine maleate
Page last updated: 2024-08-01 09:27:58

prochlorperazine maleate

Description

prochlorperazine maleate : no description available [CHeBI]

Cross-References

ID SourceID
PubMed CID5281032
CHEMBL ID1314751
SCHEMBL ID40755
CHEBI ID8436
MeSH IDM0354121

Synonyms (91)

Synonym
CHEBI:8436 ,
c20h24cln3s.2c4h4o4
EU-0101034
stemetil dimaleate
pasotomin
emetiral
2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine maleate (1:2)
nibromin a
einecs 201-511-3
prochlorperazinu dimaleat [czech]
phenothiazine, 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-, maleate (1:2)
10h-phenothiazine, 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-, (z)-2-butenedioate (1:2)
meterazin maleate
prochlorperazine dimaleate
PRESTWICK_410
84-02-6
compazine (tn)
D00479
prochlorperazine maleate (jp17/usp)
NCGC00094323-01
prochlorperazine dimaleate salt
P 9178
HMS1569O19
HMS2096O19
HMS3263O09
unii-i1t8o1jtl6
prochlorperazine maleate [usp:jan]
i1t8o1jtl6 ,
nsc 748866
dtxcid6028941
dtxsid1049015 ,
tox21_113522
S4631
NCGC00015856-08
maleate, prochlorperazine
sr-01000000260
prochlorperazine, dimaleate
LP01034
prochlorperazine maleate [mart.]
prochlorperazine maleate [ep monograph]
prochlorperazine dimaleate [mi]
10h-phenothiazine, 2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-, (2z)-2-butenedioate (1:2)
2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine maleate (1:2).
prochlorperazine maleate [usp impurity]
prochlorperazine maleate [green book]
prochlorperazine maleate [usp monograph]
prochlorperazine maleate [jan]
prochlorperazine dimaleate [green book]
prochlorperazine maleate [who-dd]
prochlorperazine maleate [orange book]
prochlorperazine maleate [vandf]
prochlorperazine maleate [usp-rs]
CCG-222338
CCG-220399
SCHEMBL40755
tox21_113522_1
NCGC00015856-10
NCGC00261719-01
tox21_501034
prochlorperazin-dimaleat
2-chloro-10-[3[(4-methyl-1-piperazinyl)propyl]-10h-phenothiazine dimaleate
prochlorperazine maleate, british pharmacopoeia (bp) reference standard
AKOS024457528
CHEMBL1314751
mfcd00069330
prochlorperazine maleate, united states pharmacopeia (usp) reference standard
prochlorperazine maleate, european pharmacopoeia (ep) reference standard
SR-01000000260-9
SR-01000000260-2
HMS3713O19
2-chloro-10-(3-(4-methylpiperazin-1-yl)propyl)-10h-phenothiazine dimaleate
HB1907
2-chloro-10-[3[(4-methyl-1-piperazi nyl)propyl]-10h-phenothiazine dimaleate
Q27108082
AS-13744
2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine dimaleate
P2368
bis((2z)-but-2-enedioic acid); 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10h-phenothiazine
HMS3885J12
prochlorperazinedimaleate
EN300-749530
BP165885
Z2568619526
procomp
prochlorperazine maleate (ep monograph)
2-chloro-10-(3-(4-methylpiperazin-1-yl)propyl)-10h-phenothiazine di((2z)-but-2-enedioic acid)
prochlorperazine maleate (mart.)
2-chloro-10-(3-(4-methylpiperazin-1-yl)propyl)-10h-phenothiazine dimaleate
prochlorperazine maleate (usp-rs)
prochlorperazine maleate (usp impurity)
prochlorperazine maleate (usp monograph)

Drug Classes (1)

ClassDescription
maleate saltSalts from maleic acid.

Protein Targets (47)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.8107AID2147
endonuclease IVEscherichia coliPotency7.0795AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency18.8876AID588453
RAR-related orphan receptor gammaMus musculus (house mouse)Potency27.7250AID1159521; AID1159523
Fumarate hydrataseHomo sapiens (human)Potency35.4813AID1347053
TDP1 proteinHomo sapiens (human)Potency3.8586AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency16.4695AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency28.1838AID1460
AR proteinHomo sapiens (human)Potency28.3038AID743035; AID743042; AID743054; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency28.6008AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency4.8568AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency23.7101AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency15.4871AID1645841
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency56.2341AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency27.9238AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency26.9501AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency10.0940AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency25.9413AID1224819; AID1224820; AID1224821; AID1224823; AID1224848; AID1224849; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency26.7776AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency16.7855AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency26.2399AID743069; AID743078; AID743079
cytochrome P450 2D6Homo sapiens (human)Potency0.1549AID1645840
polyproteinZika virusPotency35.4813AID1347053
glucocerebrosidaseHomo sapiens (human)Potency22.3872AID2101
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency33.4889AID743191
aryl hydrocarbon receptorHomo sapiens (human)Potency11.6470AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency29.8493AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency26.6032AID1259385; AID1259395
activating transcription factor 6Homo sapiens (human)Potency26.8325AID1159516
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency23.4643AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency60.1993AID1224845; AID1224896
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency37.9330AID1967
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency0.7943AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency6.8131AID743065; AID743067
mitogen-activated protein kinase 1Homo sapiens (human)Potency39.8107AID1454
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency33.4889AID743202
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency2.8184AID588590
gemininHomo sapiens (human)Potency10.8946AID463097; AID504364
survival motor neuron protein isoform dHomo sapiens (human)Potency12.5893AID1458
M-phase phosphoprotein 8Homo sapiens (human)Potency25.1189AID488949
lamin isoform A-delta10Homo sapiens (human)Potency14.5015AID1459; AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency15.8489AID1461
Cellular tumor antigen p53Homo sapiens (human)Potency33.4915AID651631; AID720552
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency22.3872AID1479145
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency7.9433AID1457
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency31.0399AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency29.8493AID651632

Bioassays (40)

Assay IDTitleYearJournalArticle
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression2022The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560		Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
ISSN: 1083-351X		Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
ISSN: 2211-1247		A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
ISSN: 1083-351X		Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1745845Primary qHTS for Inhibitors of ATXN expression2022The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937		High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553		Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
ISSN: 1932-6203		Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60ISSN: 1873-3913A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
ISSN: 1932-6203		Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937		High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
ISSN: 1932-6203		Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
ISSN: 1464-3405		Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
ISSN: 1872-9096		High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
ISSN: 1552-454X		A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2022Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 37, Issue:1
ISSN: 1475-6374

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (50.00)24.3611
2020's7 (50.00)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
clothiapine
0
maleate salt00low000000
timolol maleate
0
maleate saltanti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist		00low000000
brompheniramine maleate
0
maleate saltanti-allergic agent00low000000
trimipramine maleate
0
maleate saltantidepressant00low000000
carbinoxamine maleate
0
maleate saltanti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist		00low000000
enalapril maleate
0
maleate saltantihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug		00low000000
dizocilpine maleate
0
maleate salt;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist		00low000000
paroxetine maleate
0
maleate saltantidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor		00low000000
ergonovine maleate
0
maleate saltdiagnostic agent;
oxytocic		00low000000
trifluoperazine dimaleate
0
maleate salt00low000000
cgs 12066b
0
maleate saltprodrug;
serotonergic agonist		00low000000
beta-aminoarteether maleate
0
maleate saltallergen00low000000
tegaserod maleate
0
maleate saltserotonergic agonist00low000000
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Congenital Zika Syndrome0
1
202020204.0medium000010
Disease Models, Animal0
1
202020204.0medium000010
Encephalitis, Polio0
1
2011201113.0medium000010
Malaria, Falciparum0
1
2014201410.0medium000010
Plasmodium falciparum Malaria0
1
2014201410.0medium000010
Poliomyelitis0
1
2011201113.0medium000010
Zika Virus Infection0
1
202020204.0medium000010

Bioavailability (1)

ArticleYear
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, , 11-15, Volume: 294, Issue:46		2019